|
August 9, 2022
|
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
|
|
|
August 3, 2022
|
Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
|
|
|
July 27, 2022
|
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
|
|
|
May 16, 2022
|
Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)
|
|
|
May 9, 2022
|
Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update
|
|
|
May 5, 2022
|
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
|
|
|
April 13, 2022
|
Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting
|
|
|
April 7, 2022
|
Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
|
|
|
March 15, 2022
|
Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel
|
|
|
March 8, 2022
|
Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting
|
|
